Alnylam Pharmaceuticals (United States)

Alnylam Pharmaceuticals (United States)

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2022. Read More.


Open Access Percentage

65%


Total
Publications

659


Total Open
Publications

429


Total
Citations

59K


Open Access
Percentage

65%


Total
Publications

659


Total Open
Publications

429


Total
Citations

59K

Wikipedia

Website

download

Breakdown

16% 36% 13% 35%

Publisher Open

16%

Both

36%

Other Platform Open

13%

Closed

35%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
20032004200520062007200820092010201120122013201420152016201720182019202020212022

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0102030405060708090Total Publications
20032004200520062007200820092010201120122013201420152016201720182019202020212022

Open

Closed

Publisher Open

31%OA Journal

OA Journal 31%

106

Hybrid 31%

106

No Guarantees 38%

133

Other Platform Open

Domain 84%

269

Institution 27%

87

Other Internet 12%

38

Preprint 11%

36

Public 8%

26

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
266
Europe PMC
Domain
208
Massachusetts Institute of Technology - DSpace@MIT
Institution
26
Semantic Scholar
Public
20
bioRxiv
Preprint
20
University College London - UCL Discovery
Institution
14
DOI
Other Internet
14
Harvard University - Digital Access to Scholarship at Harvard (DASH)
Institution
13
medRxiv
Preprint
10
Figshare
Public
10
1 / 8

Data updated 31 August 2023

Share

Share

Share